IHS Chemical Week

EnviroTech :: Biotech

Teva to Acquire Ratiopharm for $4.9 Billion

10:46 PM MDT | March 18, 2010 | Deepti Ramesh

Teva Pharmaceutical Industries (Petah Tikva, Israel), the leading generics pharmaceutical company in the world, says it has entered into a definitive agreement to acquire Ratiopharm (Ulm, Germany), the second largest generics producer in Germany and the sixth largest generics drug company worldwide, for an enterprise value of €3.62 billion ($4.9 billion). Teva expects to complete the acquisition by the end of 2010. The acquisition will position Teva as the leading generics company in Europe, Teva says. Ratiopharm had sales of about €1.6 billion ($2.2...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa